Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Fischer

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
Organic & Biomolecular Chemistry|October 31, 2014
A facile approach to tryptophan derivatives for the total synthesis of argyrin analoguesChou-Hsiung Chen, Sivaneswary Genapathy, Peter M Fischer, et al.
Journal of Pharmaceutical Sciences|July 3, 2016
Support Tools in Formulation Development for Poorly Soluble DrugsGudrun A Fridgeirsdottir, Robert Harris, Peter M Fischer, et al.
Molecules (Basel, Switzerland)|September 28, 2024
Discovery of Substituted 5-(2-Hydroxybenzoyl)-2-Pyridone Analogues as Inhibitors of the Human Caf1/CNOT7 RibonucleaseIshwinder Kaur, Gopal P Jadhav, Peter M Fischer, et al.
Journal of Molecular Biology|July 17, 2007
Crystallographic and mass spectrometric characterisation of eIF4E with N7-alkylated cap derivativesChristopher J Brown, Iain McNae, Peter M Fischer, et al.
Journal of Pharmaceutical Sciences|October 16, 2016
Erratum to "Survival of the Fittest: Time-To-Event Modelling of Crystallisation of Amorphous Poorly Soluble Drugs"Katarzyna Nurzyńska, Rupert P Austin, Peter M Fischer, et al.
Assay and Drug Development Technologies|January 21, 2010
A Cy5-labeled S100A10 tracer used to identify inhibitors of the protein interaction with annexin A2Chan Li, Tummala R K Reddy, Peter M Fischer, et al.
Journal of Pharmaceutical Sciences|May 31, 2016
Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble DrugsKatarzyna Nurzyńska, Rupert P Austin, Peter M Fischer, et al.
Biochemical Society Transactions|January 23, 2008
Exploiting glycogen synthase kinase 3beta flexibility in molecular recognitionMichael P Mazanetz, Ian M Withers, Charles A Laughton, et al.
Chemmedchem|May 31, 2012
Three-dimensional pharmacophore design and biochemical screening identifies substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interactionTummala R K Reddy, Chan Li, Peter M Fischer, et al.
International Journal of Cancer|April 13, 2011
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridolXiangrui Liu, Shenhua Shi, Frankie Lam, et al.
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
Organic & Biomolecular Chemistry|October 31, 2014
A facile approach to tryptophan derivatives for the total synthesis of argyrin analoguesChou-Hsiung Chen, Sivaneswary Genapathy, Peter M Fischer, et al.
Journal of Pharmaceutical Sciences|July 3, 2016
Support Tools in Formulation Development for Poorly Soluble DrugsGudrun A Fridgeirsdottir, Robert Harris, Peter M Fischer, et al.
Molecules (Basel, Switzerland)|September 28, 2024
Discovery of Substituted 5-(2-Hydroxybenzoyl)-2-Pyridone Analogues as Inhibitors of the Human Caf1/CNOT7 RibonucleaseIshwinder Kaur, Gopal P Jadhav, Peter M Fischer, et al.
Journal of Molecular Biology|July 17, 2007
Crystallographic and mass spectrometric characterisation of eIF4E with N7-alkylated cap derivativesChristopher J Brown, Iain McNae, Peter M Fischer, et al.
Journal of Pharmaceutical Sciences|October 16, 2016
Erratum to "Survival of the Fittest: Time-To-Event Modelling of Crystallisation of Amorphous Poorly Soluble Drugs"Katarzyna Nurzyńska, Rupert P Austin, Peter M Fischer, et al.
Assay and Drug Development Technologies|January 21, 2010
A Cy5-labeled S100A10 tracer used to identify inhibitors of the protein interaction with annexin A2Chan Li, Tummala R K Reddy, Peter M Fischer, et al.
Journal of Pharmaceutical Sciences|May 31, 2016
Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble DrugsKatarzyna Nurzyńska, Rupert P Austin, Peter M Fischer, et al.
Biochemical Society Transactions|January 23, 2008
Exploiting glycogen synthase kinase 3beta flexibility in molecular recognitionMichael P Mazanetz, Ian M Withers, Charles A Laughton, et al.
Chemmedchem|May 31, 2012
Three-dimensional pharmacophore design and biochemical screening identifies substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interactionTummala R K Reddy, Chan Li, Peter M Fischer, et al.
International Journal of Cancer|April 13, 2011
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridolXiangrui Liu, Shenhua Shi, Frankie Lam, et al.
Pageof 12